ReviewFrontiers in immunology2026
Unraveling fibrinogen-like protein 1's role in immune regulation.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hepassocin (FGL-1) as a Hepatokine in Liver Physiology and Metabolic Dysfunction: A Narrative Review.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrinogen-like protein 1 (FGL1) has been recently identified as an emerging novel checkpoint ligand of lymphocyte activation gene-3 (LAG-3) with important immunoregulatory functions. In addition to LAG-3, FGL1 also interacts with bone morphogenetic protein 6 (BMP6), activin receptor-like kinase 5 (ALK5) and other unidentified receptors to perform biological functions. Physiologically, FGL1 restrains intrahepatic immunity and preserves tolerance. Pathologically, FGL1 is frequently upregulated in various tumors and autoimmune diseases and is closely related to the occurrence and development of these diseases. Targeting FGL1 has shown preclinical efficacy in enhancing immunotherapy involving programmed death ligand 1 (PD-L1)/PD-1 checkpoint blockade, inhibiting liver metastasis and relieving autoimmunity without overt hepatotoxicity. In this review, we summarize recent advances in FGL1, focus on the immunoregulatory functions of FGL1, and evaluate its potential as a therapeutic target for immune-related diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.